Approval of Ocrelizumab
As of this week, Ocrevus® (Ocrelizumab) is available for prescription and in pharmacies for the treatment of relapsing-remitting (RMS) and primary progressive Multiple Sclerosis (PPMS). Given the good clinical efficacy data and acceptable safety profile,
Continue reading





